4 citations
,
January 2024 in “The Scientific World JOURNAL” Understanding hair follicle development helps create treatments for hair loss and improve hair health.
December 2025 in “Journal of health economics and outcomes research” Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.
20 citations
,
December 2020 in “Frontiers in Immunology” The immune processes causing VKH and vitiligo are similar in dogs and humans.
19 citations
,
July 2022 in “PNAS Nexus” Similar treatments might work for different types of scarring hair loss.
January 2026 in “Pharmaceutics” New drug delivery systems show promise in effectively treating pathological scars.
January 2025 in “Biomedicines” High testosterone levels can harm fertility by disrupting the LIF signaling pathway in the uterus.
1 citations
,
April 2015 in “InTech eBooks” RAGE is a potential target for melanoma treatment, but its effectiveness is uncertain due to variable expression levels.
123 citations
,
January 2012 in “The Keio Journal of Medicine” Anti-angiogenic therapy can help treat cancer but may cause resistance and side effects, so alternative methods are being explored.
1 citations
,
May 2022 in “IntechOpen eBooks” Natural products might help treat COVID-19, but current drugs like hydroxychloroquine haven't worked.
11 citations
,
July 2015 in “Frontiers in Cellular Neuroscience” Corticosterone makes ethanol more effective at blocking brain processes important for learning and memory.
45 citations
,
January 2020 in “International Journal of Molecular Sciences” Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.
23 citations
,
April 2016 in “American Journal of Pathology” The research suggests that a specific skin gene can be controlled by signals within and between cells and is wrongly activated in certain skin diseases.
22 citations
,
May 2021 in “Nature Communications” Tissue stiffness affects hair follicle regeneration, and Twist1 is a key regulator.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
20 citations
,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
17 citations
,
April 2020 in “Dermatology and Therapy” The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
July 2017 in “British Journal of Dermatology” The document concludes that scalp conditions have various causes and can present in many different ways.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
5 citations
,
February 2024 in “Clinical Pharmacokinetics”